loading
Precedente Chiudi:
$7.22
Aprire:
$7.17
Volume 24 ore:
3.35M
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.47B
Reddito:
$331.41M
Utile/perdita netta:
$-226.54M
Rapporto P/E:
-6.2712
EPS:
-1.18
Flusso di cassa netto:
$-97.31M
1 W Prestazione:
+15.44%
1M Prestazione:
-4.39%
6M Prestazione:
-1.20%
1 anno Prestazione:
+61.57%
Intervallo 1D:
Value
$7.14
$7.51
Intervallo di 1 settimana:
Value
$6.33
$7.51
Portata 52W:
Value
$4.03
$9.50

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
Nome
Biocryst Pharmaceuticals Inc
Name
Telefono
919-859-1302
Name
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
Dipendente
580
Name
Cinguettio
@biocrystpharma
Name
Prossima data di guadagno
2025-02-24
Name
Ultimi documenti SEC
Name
BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
7.40 1.47B 331.41M -226.54M -97.31M -1.18
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
148.67 67.28B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.22 45.62B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.71 45.01B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.65 15.60B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
284.73 12.77B 2.76B 1.11B 898.10M 22.77

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-25 Iniziato Wedbush Outperform
2023-11-20 Ripresa JP Morgan Overweight
2023-09-18 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-08-04 Aggiornamento Jefferies Hold → Buy
2023-07-13 Aggiornamento BofA Securities Neutral → Buy
2023-02-22 Aggiornamento Needham Hold → Buy
2022-11-02 Aggiornamento Evercore ISI In-line → Outperform
2022-08-05 Downgrade Evercore ISI Outperform → In-line
2022-08-05 Downgrade Oppenheimer Outperform → Perform
2022-04-18 Downgrade Barclays Overweight → Equal Weight
2022-04-11 Downgrade BofA Securities Buy → Neutral
2021-12-10 Iniziato Oppenheimer Outperform
2021-08-06 Downgrade Jefferies Buy → Hold
2021-08-03 Iniziato Cantor Fitzgerald Overweight
2021-03-01 Iniziato Cowen Outperform
2020-09-29 Ripresa JP Morgan Overweight
2020-06-17 Iniziato BTIG Research Neutral
2020-05-05 Aggiornamento Barclays Equal Weight → Overweight
2019-11-15 Aggiornamento BofA/Merrill Neutral → Buy
2019-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
2018-11-16 Ripresa Piper Jaffray Overweight
2018-08-08 Ripresa JP Morgan Overweight
2018-07-17 Aggiornamento BofA/Merrill Underperform → Neutral
2018-06-22 Iniziato Seaport Global Securities Neutral
2018-01-02 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2017-12-20 Iniziato Barclays Equal Weight
2017-09-15 Iniziato RBC Capital Mkts Sector Perform
2017-09-06 Aggiornamento JP Morgan Neutral → Overweight
2017-09-06 Aggiornamento Jefferies Hold → Buy
2017-02-16 Iniziato Ladenburg Thalmann Buy
2016-08-12 Aggiornamento Piper Jaffray Neutral → Overweight
2016-08-04 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Reiterato FBR Capital Outperform
2016-02-09 Downgrade JP Morgan Overweight → Neutral
2016-02-09 Downgrade Needham Buy → Hold
Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

pulisher
Apr 17, 2025

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st

Apr 17, 2025
pulisher
Apr 11, 2025

BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

BioCryst appoints interim CFO following executive departure - Investing.com

Apr 10, 2025
pulisher
Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

BioCryst at Needham Conference: Growth Amidst Competition - Investing.com

Apr 09, 2025
pulisher
Apr 04, 2025

(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 04, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

BioCryst to Present at Upcoming Investor Conference - The Manila Times

Apr 03, 2025
pulisher
Apr 02, 2025

BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.

Apr 02, 2025
pulisher
Apr 01, 2025

Biocryst discovers new KLK5 inhibitors - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 27, 2025

BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews

Mar 27, 2025
pulisher
Mar 19, 2025

North Carolina biotech sues to block copies of $400M drug - The Business Journals

Mar 19, 2025
pulisher
Mar 18, 2025

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego

Mar 18, 2025
pulisher
Mar 18, 2025

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St

Mar 18, 2025
pulisher
Mar 14, 2025

(BCRX) Technical Data - news.stocktradersdaily.com

Mar 14, 2025
pulisher
Mar 14, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com

Mar 12, 2025
pulisher
Mar 11, 2025

BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

BioCryst sues to protect ORLADEYO patents - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com

Mar 11, 2025
pulisher
Mar 09, 2025

Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com

Mar 09, 2025
pulisher
Mar 09, 2025

Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst reports inducement grants under Nasdaq listing rule - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

CFO Anthony Doyle resigns at Biocryst - BioCentury

Mar 05, 2025
pulisher
Mar 04, 2025

BioCryst CFO resigns, search for successor begins - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks

Mar 04, 2025

Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$27.00
price down icon 0.74%
$101.32
price up icon 0.80%
$7.56
price up icon 2.30%
$101.38
price up icon 1.28%
drug_manufacturers_specialty_generic RDY
$13.67
price up icon 1.71%
$284.73
price down icon 0.16%
Capitalizzazione:     |  Volume (24 ore):